Asston Pharmaceuticals Ltd (APL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Asston Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Change in registered office address
Others (Uncategorized) · 13 Oct 2026, 10:48 pm
Asston Pharmaceuticals Approves Relocation of Registered Office Within Navi Mumbai The Board of Directors of Asston Pharmaceuticals Limited approved shifting the company's registered office within local city limits and under the same Registrar of Companies, effective 15th Oct'26. The office will relocate from CBD Belapur, Navi Mumbai (400614) to Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai (410210).
Outcome of the Board held on 13th October, 2026.
Outcome · 13 Oct 2026, 10:45 pm
Asston Pharmaceuticals Approves Shifting of Registered Office Within Navi Mumbai The Board of Directors of Asston Pharmaceuticals Limited approved shifting the company's registered office within local limits, effective 15th Oct'26. The office will move from CBD Belapur, Navi Mumbai, to Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai. The change remains within the local limits of the same city and under the jurisdiction of the same Registrar of Companies.
Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/10/2026 ,inter alia, to consider and approve matters as attached
Intimation · 06 Oct 2026, 11:56 pm
Asston Pharmaceuticals Schedules Board Meeting on 13th Oct'26 for Property Acquisition Asston Pharmaceuticals Limited announced that its Board of Directors will meet on 13th Oct'26. The agenda includes considering and approving the acquisition of immovable property via a bank or financial institution auction. Additionally, the board will deliberate on shifting the company's registered office address alongside other incidental corporate matters.
Change in Management
Change in Management · 01 Oct 2026, 7:33 pm
Asston Pharmaceuticals Approves Key Appointments, Auditor Change, and Remuneration Hikes at AGM Asston Pharmaceuticals shareholders approved key resolutions at the AGM on 29th Sep'26. Members adopted the audited standalone financial statements for the fiscal ended 31st Mar'26 and approved the re-appointment of Managing Director Ashish Narayan Sakalkar, retiring by rotation. The company appointed M/s Panchal S K & Associates as Statutory Auditors. Additionally, shareholders approved remuneration increases for MD Ashish Narayan Sakalkar, Whole-time Director & CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh.
Appointment of Statutory Auditor of the Company
Change in Auditor · 01 Oct 2026, 7:32 pm
Asston Pharmaceuticals Approves Auditor Appointment and Key Executive Remuneration Hikes At its 7th Annual General Meeting on 29th Sep'26, Asston Pharmaceuticals Limited secured shareholder approval to adopt FY26 audited standalone financial statements and re-appoint Managing Director Ashish Narayan Sakalkar, retiring by rotation. Members approved the appointment of M/s Panchal S K & Associates as Statutory Auditors. Additionally, shareholders sanctioned remuneration increases for Managing Director Ashish Narayan Sakalkar, Whole-time Director and CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh.
Scrutinizer Report
Annual General Meeting · 01 Oct 2026, 6:31 pm
Asston Pharmaceuticals Approves All Resolutions at 7th AGM Asston Pharmaceuticals Limited announced that shareholders approved all six resolutions at its 7th AGM held on 29th Sep'26 with 100% favorable votes via remote e-voting. Passed ordinary resolutions include the adoption of FY26 audited financial statements, the reappointment of Managing Director Ashish Narayan Sakalkar retiring by rotation, and the appointment of M/s Panchal S K & Associates as statutory auditors. Special resolutions approving remuneration hikes for Managing Director Ashish Narayan Sakalkar, Whole Time Director and CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh also passed unanimously.
Outcome of 7th Annual General Meeting
Annual General Meeting · 29 Sept 2026, 6:44 pm
7th Annual Report of Asston Pharmaceuticals Limited for the Financial Year 2025-26.
Others (Uncategorized) · 07 Sept 2026, 11:37 pm
Notice of 7th Annual General Meeting scheduled to be held on 29th September, 2026 at 12:30 P.M.
Annual General Meeting · 07 Sept 2026, 11:12 pm
Allotment of 24,10,431 equity shares via Preferential Allotment
Others (Uncategorized) · 05 Sept 2026, 6:43 pm
Asston Pharmaceuticals Approves Preferential Allotment of 24.10 Lakh Equity Shares On 5th Sep'26, Asston Pharmaceuticals approved the preferential allotment of 24,10,431 equity shares of face value Rs. 10 each at an issue price of Rs. 115 per share (including a premium of Rs. 105 per share) for cash to 15 public investors. Key allottees include Vijay Rathee (13,17,391 shares) and Vijaylaxmi Infra Projects (7,82,608 shares). Post-allotment, the company's paid-up equity share capital increased to Rs. 10,92,27,910, consisting of 1,09,22,791 equity shares.
Allotment of 24,10,431 equity shares via Preferential Allotment
Others (Uncategorized) · 05 Sept 2026, 6:39 pm
Asston Pharmaceuticals Approves Preferential Allotment of 24.10 Lakh Equity Shares On 5th Sep'26, Asston Pharmaceuticals approved the preferential allotment of 24,10,431 equity shares (face value Rs. 10 each) at an issue price of Rs. 115 per share, including a premium of Rs. 105 per share, for cash to 15 public investors. Key allottees include Vijay Rathee (13,17,391 shares) and Vijaylaxmi Infra Projects Private Limited (7,82,608 shares). Post-allotment, the company's paid-up equity share capital expanded to Rs. 10,92,27,910, comprising 1,09,22,791 equity shares. The newly allotted shares rank pari passu with existing equity shares.
Fixing Record date/Cut-off date to determine eligible shareholders for the E-voting facility for the 7th Annual General Meeting of the Company
Others · 05 Sept 2026, 1:14 am
Fixing 29th September, 2026, as the date for convening the 7th Annual General Meeting of the Company.
Annual General Meeting · 05 Sept 2026, 1:09 am
Meeting Update
Others (Uncategorized) · 05 Sept 2026, 1:06 am
Asston Pharmaceuticals Board Approves Auditor Appointments, Remuneration Hikes, and AGM Asston Pharmaceuticals' board approved the appointment of M/s Panchal S K & Associates as Statutory Auditors and M/s Yash A. Jain & Associates as Internal Auditors on 4th Sep'26. The board recommended the reappointment of MD Ashish Narayan Sakalkar and proposed remuneration hikes for Sakalkar, Whole-time Director & CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh, subject to shareholder approval. The 7th AGM is scheduled for 29th Sep'26 via video conferencing, with the e-voting cut-off set for 22nd Sep'26.
Change in Management
Change in Management · 05 Sept 2026, 1:05 am
Asston Pharmaceuticals Board Approves Key Appointments and Remuneration Hikes Asston Pharmaceuticals' board approved key governance decisions at its meeting on 4th Sep'26, including the appointment of M/s Panchal S K & Associates as Statutory Auditors and M/s Yash A. Jain & Associates as Internal Auditors. The board recommended the re-appointment of MD Ashish Narayan Sakalkar, who retires by rotation, and approved proposed remuneration hikes for the MD, Whole-time Director & CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh. The 7th AGM is scheduled for 29th Sep'26, with 22nd Sep'26 set as the e-voting cut-off date.
Appointment of Statutory Auditor
Change in Auditor · 05 Sept 2026, 1:03 am
Asston Pharmaceuticals Board Approves Key Appointments, Remuneration Hikes, and AGM Date Asston Pharmaceuticals Limited's board approved on 4th Sep'26 the appointment of M/s Panchal S K & Associates as Statutory Auditors and M/s Yash A. Jain & Associates as Internal Auditors. The board recommended the reappointment of Managing Director Ashish Narayan Sakalkar, retiring by rotation, and proposed remuneration increases for Sakalkar, Whole-time Director & CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh, subject to shareholder approval. The 7th AGM is scheduled for 29th Sep'26, with an e-voting cut-off date of 22nd Sep'26.
Outcome of the Board Meeting.
Outcome · 05 Sept 2026, 1:01 am
Asston Pharmaceuticals Approves Auditor Appointments and Key Remuneration Hikes The Board of Asston Pharmaceuticals approved the appointment of M/s Panchal S K & Associates as Statutory Auditors and M/s Yash A. Jain & Associates as Internal Auditors on 4th Sep'26. The board recommended the reappointment of Managing Director Ashish Narayan Sakalkar and approved remuneration hikes for the Managing Director, Whole-time Director & CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh, subject to shareholder approval. The company's 7th AGM is scheduled for 29th Sep'26, with 22nd Sep'26 fixed as the e-voting cut-off date.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Acquisition/ Disposal of Shares · 04 Sept 2026, 4:45 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Acquisition/ Disposal of Shares · 02 Sept 2026, 5:06 pm
Prakruti R Pali Acquires 1.93% Stake in Asston Pharmaceuticals Non-promoter Prakruti R Pali acquired 1,64,000 equity shares (a 1.93% stake) of Asston Pharmaceuticals Limited through an open market transaction on 28th Aug'26. This purchase increases Pali's total holding in the BSE SME-listed company from 4,54,000 shares (5.33%) to 6,18,000 shares, representing 7.26% of the total voting capital. The shares acquired are fully paid-up equity, with the official regulatory disclosure filed on 1st Sep'26.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Acquisition/ Disposal of Shares · 01 Sept 2026, 4:13 pm
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Acquisition/ Disposal of Shares · 31 Aug 2026, 9:40 pm
Prakruti R Pali Acquires 2.82% Stake in Asston Pharmaceuticals Prakruti R Pali acquired 2.82% of Asston Pharmaceuticals Ltd., purchasing 2,40,000 equity shares via an open market transaction on 27 Aug'26. This acquisition increases Pali's total holding from 2,14,000 shares (2.51%) to 4,54,000 shares (5.33%). The acquirer does not belong to the promoter group. The target company's shares are listed on the Bombay Stock Exchange SME Platform. This disclosure was made under SEBI's SAST Regulations, 2011.
Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. Appointment of M/s ....
Intimation · 28 Aug 2026, 1:54 am
Voting Result and Scrutinizer report for EGM held on 31st July, 2026 through VC-OAVM
Extra Ordinary General Meeting · 04 Aug 2026, 1:14 am
Asston Pharmaceuticals Shareholders Approve Preferential Equity Issuance Asston Pharmaceuticals announced that shareholders have approved a special resolution to issue equity shares on a preferential basis. The resolution passed with 100% of votes in favor at the Extraordinary General Meeting held on 31st Jul'26. A total of 4,682,584 votes were polled, representing 55.01% of the total outstanding shares. Both the promoter group and public shareholders voted entirely in favor of the proposal, with no votes against and no invalid votes recorded. The EGM was attended by 10 shareholders via video conferencing.
Outcome and Proceedings of the 2nd Extraordinary General Meeting for F.Y. 2026-27, scheduled to be held on 31st July, 2026, at 12:30 P.M. through Video Conferencing and Other Audio-Visual Means.
Extra Ordinary General Meeting · 31 Jul 2026, 6:45 pm
Asston Pharma EGM Held to Approve Preferential Equity Share Issue Asston Pharmaceuticals held its 2nd EGM for FY27 on 31-Jul-26 to consider and approve a special resolution for issuing equity shares on a preferential basis. The meeting was conducted virtually, and shareholders voted via remote e-voting and e-voting during the EGM. The remote e-voting period ran from 28-Jul-26 to 30-Jul-26. The final voting results, along with the Scrutinizer's Report, will be announced and submitted to the stock exchange within two working days of the meeting's conclusion.
Notice of Second Extraordinary General Meeting for F.Y. 2026-27
Extra Ordinary General Meeting · 09 Jul 2026, 10:18 pm
Asston Pharma to Raise ₹27.72 Crore via Preferential Allotment of Equity Shares Asston Pharmaceuticals will hold an EGM on 31st Jul'26 to approve a preferential issue of 24,10,431 equity shares. The shares, priced at ₹115 each, will raise up to ₹27.72 crore. The issue price includes a ₹105 premium over the ₹10 face value. Funds will be used for working capital (₹19.22 Cr), debt repayment (₹2.00 Cr), capex (₹2.00 Cr), and general corporate purposes (₹4.50 Cr). The allotment is to non-promoters, and the promoter group's holding will dilute from 50.66% to 39.48% post-issue.